PerspectiveBACTERIAL DISEASE

Preventing Newborn Infection with Maternal Immunization

See allHide authors and affiliations

Science Translational Medicine  24 Jul 2013:
Vol. 5, Issue 195, pp. 195ps11
DOI: 10.1126/scitranslmed.3005451
  • Fig. 1

    Mapping neonatal disease. The estimated number of cases of GBS infection per 1000 live births in infants <90 days of age is indicated in different colors. Countries in gray do not have incidence data available. Adapted from data reviewed by Edmond et al. (21).

    CREDIT: G. CORSI/NOVARTIS VACCINES
  • Table 1 Serotype survey.

    Shown is the potential coverage (percent) of a trivalent GBS vaccine in various countries. Data are extrapolated from (16) and (21).

    Early-onset disease Late-onset disease
    Serotype USAGermanyUKS AfricaMalawiUSAGermanyUKS AfricaMalawi
    Ia30173223262411171420
    Ib7565774704
    III28583758525177678472
    Trivalent
    (Ia+Ib+III)
    65807586858292929896
  • Table 2

    Needs assessment and recommendations.

    Working group Needs and recommendations
    GBS epidemiology and vaccine need in developed countries • Standardize surveillance data throughout Europe
    • Raise awareness of GBS disease
    GBS epidemiology and vaccine need in developing countries • Standardize surveillance worldwide
    • Arrange PCR or culture-free testing
    • Set up studies to assess true disease burden
    Moving forward with a maternal immunization platform • Collect epidemiology data to drive decision-making
    • Evaluate the impact of maternal immunization on natural infection and response to vaccines in infants
    • Assess duration of protection provided to infants by maternal immunization
    • Study correlates of protection to estimate extent of achievable protection in infants
    • Educate mothers, providers, and public health officials about the need for vaccination and vaccine safety
    Optimal phase 3 trial design for a GBS vaccine in pregnant women • A trial should simulate real-world use of vaccine to assess potential impact
    • Define optimal time in pregnancy to vaccinate
    • Assess impact not only on GBS disease but other pregnancy outcomes such as prematurity
    • Identify sites with large disease burden but adequate laboratory facilities

Additional Files

  • Supplementary Material for:

    Preventing Newborn Infection with Maternal Immunization

    Steven Black1, Immaculada Margarit2, Rino Rappuoli2*

    *Corresponding Author. E-mail: rino.rappuoli@novartis.com

    Published 24 July 2013, Sci. Transl. Med. 5, 195ps11 (2013)
    DOI: 10.1126/scitranslmed.3005451

    This PDF file includes:

    • Table S1: Novartis patents pertaining to GBS vaccine development.

    [Download PDF]

    [Table S1]

     

Navigate This Article